Tenet Healthcare Corporation (THC) Stock Analysis

74.0/100
Buy Not Halal Healthcare
Price $286.03
Market Cap $22.76B
52-Week Change +45.44%

Is THC a good investment?

Tenet Healthcare Corporation (THC) has a Plutrex AI rating of 74.0/100 as of November 12, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Profitability leadership vs. peers: Operating margin 19.12% (+47.7% vs. industry 12.94%), net margin 13.09% (+96.4% vs. industry 6.67%), ROE 61.3% (+268.4% vs. industry 16.64%) — FCF of $3.33B confirms this is real cash generation, not accounting artifacts; the strongest profitability profile in a 23-company peer group. Main concern: Forward growth deficit is structural and unchanged: Next-year EPS growth -9.83% vs. industry +12.30% (22.1pp deficit); 5-year EPS CAGR 9.66% vs. industry 13.18% (26.7% below peers) — this persistent growth lag fully justifies the valuation discount and limits re-rating potential; without growth acceleration, P/E expansion toward peer multiples is unlikely.

Investment Summary

THC (Tenet Healthcare) is a high-quality hospital operator trading at a deeply discounted valuation (P/E 8.50x vs. industry 15.72x, a 45.9% discount) with best-in-class margins (operating margin 19.12% vs. industry 12.94%, net margin 13.09% vs. industry 6.67%) and exceptional FCF of $3.33B. The PEG ratio of 0.88 against a 9.7% 5-year EPS growth rate signals genuine intrinsic undervaluation. However, the stock has rallied +9.1% from $268.50 to $292.97 since the prior report — now trading ABOVE the analyst consensus target of $290.25, which implies a -0.9% downside per Street estimates. This price action has materially tightened the risk/reward compared to the prior entry range of $258-$268.50. The core investment thesis remains intact: exceptional profitability, strong FCF, PEG undervaluation, and very positive news sentiment (95.5/100). The primary concerns — forward EPS contraction of -9.8% next year, D/E of 2.40 (118.6% above peer average of 1.098), and 5-year growth lagging peers (9.66% vs. 13.18%) — are unchanged. At $292.97, the stock has partially priced in the positive Q3 catalyst and sector rally, reducing upside to analyst consensus to essentially zero. HOLD for existing positions; new positions should wait for a pullback into the $278-$288 zone.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
42/100
Growth Potential
40/100
Valuation
76/100
Profitability
80/100
Debt Management
35/100
Analyst Sentiment
68/100
Technical Momentum
72/100
Insider Confidence
60/100
News Sentiment
90/100

Fundamental Analysis

THC's fundamentals present a bifurcated picture of quality vs. leverage/growth. Profitability: Operating margin 19.12% (47.7% above industry 12.94%), net margin 13.09% (96.4% above industry 6.67%), ROE 61.3% (268.4% above industry 16.64%) — genuine best-in-class. FCF of $3.33B is the most credible value anchor and dwarfs debt service obligations. Valuation: P/E 8.50x (45.9% below industry 15.72x), PEG 0.88 (66.5% below industry 2.63) — deeply discounted on both absolute and relative bases. Using FCF-based intrinsic value ($3.33B FCF at 10x multiple = $33.3B enterprise value, less net debt), the equity value could range $350-$440 on a 5-year view. Health/Leverage: D/E 2.40 vs. industry 1.098 — 118.6% above peer average, the most significant structural risk. Cash of $2.67B partially offsets. Growth: Next-year EPS growth -9.83% vs. industry +12.30% (22.1pp deficit) — the critical near-term headwind. 5-year EPS growth 9.66% vs. industry 13.18% (26.7% below peers) — persistent structural growth deficit. Revenue growth 6.50% is peer-inline. The P/E has compressed from 10.35x to 8.50x (down 17.9%) despite the stock rising 9.1%, implying earnings have risen proportionally — a bullish signal on fundamentals but the price has caught up.

News Sentiment

Tenet Healthcare is riding a wave of good news that has Wall Street buzzing. The hospital giant, known by its ticker THC, has been soaring lately — and for good reason. As one headline put it, the company 'Soars Above Buy Point As Earnings Growth Accelerates,' signaling that investors are finally warming up to this overlooked healthcare powerhouse. The political winds are blowing in Tenet's favor, too. With Democrats taking control of Congress, hospital stocks like Tenet are breathing easier. Why? Democrats have historically protected Medicare and Medicaid reimbursement rates — the lifeblood of hospital revenue — reducing the risk of painful government cuts that could squeeze profits. As one headline summarized it: 'Hospital Stocks Are Feeling Blue, in a Good Way.' But the real story is in the numbers. Tenet's Q3 earnings call didn't just beat expectations — the company actually raised its full-year 2026 outlook, a rare and powerful signal that management sees accelerating momentum. Margin gains highlighted in both the Q3 Earnings Call and the separate THC highlights report show the company is squeezing more profit from every dollar of revenue, with operating margins nearly 50% above industry peers. For everyday investors, the takeaway is straightforward: Tenet is a well-run hospital company with improving finances, political tailwinds, and a stock that the market has been undervaluing for years. The challenge now? The stock has rallied sharply, and savvy investors may want to wait for a better entry point before jumping in.

Risk Assessment

PRIMARY RISK: Stock has overshot analyst consensus target ($292.97 vs. $290.25 target), creating a situation where the Street sees modest downside at current levels. The +9.1% rally since the prior report has consumed the prior entry range ($258-$268.50) entirely. STRUCTURAL RISKS: (1) D/E of 2.40 (118.6% above peer average 1.098) — in a rising rate or revenue stress scenario, elevated leverage amplifies downside; FCF of $3.33B mitigates but does not eliminate this risk. (2) Next-year EPS contraction of -9.83% — while framed as a base-effect normalization, actual EPS declines typically attract selling pressure from institutional investors; this near-term headwind could drive a pullback to our entry zone. (3) Sector valuations 'trading above historical average multiples' per news — the hospital sector rally may be extended, creating sector-level mean-reversion risk. MITIGANTS: Exceptional FCF ($3.33B), raised 2026 outlook, favorable political backdrop (Dem Congress reducing reimbursement risk), and deeply discounted valuation vs. peers all provide downside cushion. Stop at $265 represents ~6.4% below entry midpoint of $283, below prior support levels established during the last consolidation.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is THC a halal stock?

No, Tenet Healthcare Corporation (THC) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for THC?

Tenet Healthcare Corporation (THC) has a Plutrex AI rating of 74.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is THC a good investment?

According to Plutrex AI, THC has a Buy rating (74.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in THC?

US stocks like THC can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in THC?

Plutrex AI identifies the main risks for THC by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about THC

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open THC in ElBarake